Erratum: Is the current management of severe sepsis and septic shock really evidence based? (PloS Medicine 3,9 doi:10.1371/journal.pmed.0030346);Is the current management of severe sepsis and septic shock really evidence based?

PLoS Medicine

Volumn 3, Issue 9, 2006, Pages 1488-1491

  Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; DOBUTAMINE; DOPAMINE; DROTRECOGIN; GLUCOSE; HYDROCORTISONE; HYPERTENSIVE AGENT; INSULIN; METHYLPREDNISOLONE; NORADRENALIN; STEROID; VASOACTIVE AGENT; ANTIINFECTIVE AGENT; FLUDROCORTISONE;

ANTIBIOTIC THERAPY; BLOOD TRANSFUSION; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; EVIDENCE BASED MEDICINE; FLUID THERAPY; GLUCOSE BLOOD LEVEL; HEMODYNAMICS; HUMAN; INSULIN TREATMENT; INTENSIVE CARE UNIT; LUNG VENTILATION; MEDICAL PRACTICE; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; REVIEW; SEPSIS; SEPTIC SHOCK; STATISTICAL ANALYSIS; SURVIVAL RATE; TIDAL VOLUME; TREATMENT INDICATION; TREATMENT OUTCOME; ARTICLE; CLINICAL TRIAL (TOPIC); MULTIPLE ORGAN FAILURE;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; FLUDROCORTISONE; GUIDELINES AS TOPIC; HUMANS; MULTIPLE ORGAN FAILURE; SEPSIS; SHOCK, SEPTIC;

EID: 33749005686     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030346     Document Type: Erratum

References (31)

1. Vincent JL (2004) Evidence-based medicine in the ICU: Important advances and limitations. Chest 126: 592-600.
2. Hollenberg SM, Ahrens TS, Annane D, Astiz ME, Chalfin DB, et al. (2004) Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 32: 1928-1948.
3. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, et al. (2004) Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32: 858-873.
4. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118: 146-155.
5. Dupont H, Mentec H, Sollet JP, Bleichner G (2001) Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 27: 355-362.
6. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH (2002) Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122: 262-268.
7. Rello J, Vidaur L, Sandiumenge A, Rodriguez A, Gualis B, et al. (2004) De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 32: 2183-2190.
8. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J (2000) Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 356: 2139-2143.
9. Albanese J, Leone M, Garnier F, Bourgoin A, Antonini F, Martin C (2004) Renal effects of norepinephrine in septic and nonseptic patients. Chest 126: 534-539.
10. The SAFE Study Investigators (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. New Engl J Med 350: 2247-2256.
11. Sleight P (2000) Debate: Subgroup analyses in clinical trials: Fun to look at - But don't believe them! Curr Control Trials Cardiovasc Med 1: 25-27.
12. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, et al. (2001) Intensive insulin therapy in the critically ill patient. N Engl J Med 345: 1359-1367.
13. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, et al. (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 340: 409-417.
14. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, et al. (2002) Anemia and blood transfusion in critically ill patients. JAMA 288: 1499-1507.
15. Vincent JL, Sakr Y, Le Gall JR, Gerlach H, Reinhart K, et al. (2003) Is red blood cell transfusion associated with worse outcome? Results of the SOAP study. Chest 124: 125S.
16. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, et al. (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368-1377.
17. Hebert PC, Fergusson D, Blajchman MA, Wells GA, Kmetic A, et al. (2003) Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 289: 1941-1949.
18. The ARDS Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342: 1301-1308.
19. Eichacker PQ, Gerstenberger EP, Banks SM, Cui X, Natanson C (2002) Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes. Am J Respir Crit Care Med 166: 1510-1514.
20. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, et al. (1987) The methylprednisolone severe sepsis study group: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317: 353.
21. The Veterans Administration Systemic Sepsis Cooperative Study Group (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317: 659-665.
22. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, et al. (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288: 862-871.
23. Marik PE, Zaloga GP (2003) Adrenal insuffi ciency during septic shock. Crit Care Med 31: 141-145.
24. Siraux V, De Backer D, Yalavatti G, Melot C, Gervy C, et al. (2005) Relative adrenal insuffi ciency in patients with septic shock: Comparison of low-dose and conventional corticotropin tests. Crit Care Med 33: 2479-2486.
25. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709.
26. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, et al. (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE. Crit Care Med 33: 2266-2277.
27. Mackenzie AF (2005) Activated protein C: Do more survive? Intensive Care Med 31: 1624-1626.
28. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, et al. (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353: 1332-1341.
29. Chen LM, Martin CM, Morrison TL, Sibbald WJ (1999) Interobserver variability in data collection of the APACHE II score in teaching and community hospitals. Crit Care Med 27: 1999-2004.
30. Polderman KH, Christiaans HM, Wester JP, Spijkstra JJ, Girbes AR (2001) Intra-observer variability in APACHE II scoring. Intensive Care Med 27: 1550-1552.
31. Vincent JL, O'Brian J, Wheeler A, Wittebole X, Garg R, et al. (2006) Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. Crit Care 10: R74. E-pub ahead of print.